Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 601–700 of 1,006
Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy
Lagos, G., Izar, B., & Rizvi, N. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_289967 · Cited by 61
Immune profiling of pediatric solid tumors
Terry, R. L., Meyran, D., Ziegler, D. S., Haber, M., Ekert, P. G., Trapani, J. A., & Neeson, P. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137181 · Cited by 57
Checkpoint immunotherapy in pediatrics: here, gone, and back again
Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349799 · Cited by 53
Wang, H., Liu, J., Jiang, Y., Wang, Z., Zhang, Z., Peng, J., Wang, Y., & Li, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943389 · Cited by 69
Guo, Q., Linglin, Z., Yan, N., Li, Y., Guo, C., Dang, S., Shen, X., Jian-fang, H., & Luo, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148056 · Cited by 64
The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis
Yang, S., Liu, H., Zheng, Y., Chu, H., Lu, Z., Yuan, J., & Xu, S. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s509245 · Cited by 57
“We observed prominent PLIN3 expression predominantly in tumor cells and macrophage-rich micro-regions (Figure 9A).”
Nikanjam, M., Cohen, P. R., Kato, S., Sicklick, J. K., & Kurzrock, R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy412 · Cited by 55
Immunotherapy transforms cancer treatment
Zaidi, N., & Jaffee, E. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci126046 · Cited by 53
“In fact, there seems to be a direct correlation between tumor mutational burden and response to checkpoint inhibitor therapy (13).”
Self-citationAssessment of tumor mutation burden calculation from gene panel sequencing data
Xu, Z., Dai, J., Wang, D., Lu, H. J., Dai, H., Ye, H., Gu, J., Chen, S., & Huang, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s196638 · Cited by 57
“8 However, patient response rates remain relatively low at 15 – 40%, 9 indicating a need for effective biomarkers to identify patients who are likely to respond to PD-1/PD-L1 blockade.”
Wang, H., Sové, R. J., Jafarnejad, M., Rahmeh, S., Jaffee, E. M., Stearns, V., Torres, E. T. R., Connolly, R. M., & Popel, A. S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00141 · Cited by 51
Self-citationOvercoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
Puccini, A., Battaglin, F., Iaia, M. L., Lenz, H., & Salem, M. E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000404 · Cited by 55
“14 34 92 Genetic instability due to alterations in DNA repair and replication genes can increase immunogenicity through high mutational burden with subsequent neoantigen formation.”
BackgroundJain, K. K. (2020) · Medical Principles and Practice · doi:10.1159/000511107 · Cited by 55
Ma, H., Wang, H., Sové, R. J., Wang, J., Giragossian, C., & Popel, A. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001141 · Cited by 59
Gilson, P., Levy, J., Rouyer, M., Demange, J., Husson, M., Bonnet, C., Salleron, J., Leroux, A., Merlin, J., & Harlé, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-73421-5 · Cited by 50
Epigenetic state determines inflammatory sensing in neuroblastoma
Wolpaw, A. J., Grossmann, L. D., Dessau, J. L., Dong, M. M., Aaron, B., Brafford, P. A., Volgina, D., Pascual‐Pasto, G., Rodríguez-García, A., Uzun, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102358119 · Cited by 55
Cai, M., Zhao, X., Cao, M., Ma, P., Chen, M., Wu, J., Jia, C., He, C., Fu, Y., Tan, L., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5435 · Cited by 58
“While a T-cell-inflamed tumor microenvironment is the prerequisite for host immune response and thus has been associated with clinical activity of immunotherapy [52,53,55], T-cell exhaustion as the genuine target of checkpoint-based regimens has been less studied owing to the paucity of quantitative measures.”
BackgroundMethodDanesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 56
“A strong correlation between TML and ORR with anti-PD-1 or anti-PD-L1 was found in 27 tumor types.(176) In conclusion, clinical evidence suggests that TML can be a reliable predictive biomarker of response to anti-PD-1/ PD-L1 moAbs (Table 1).”
BackgroundStoltzfus, C. R., Sivakumar, R., Kunz, L., Olin, B. E., Menietti, E., Speziale, D., Adelfio, R., Bacac, M., Colombetti, S., Perro, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726492 · Cited by 57
“…have been found to be more responsive to checkpoint blockade therapies relative to more immune excluded tumors, such as pancreatic ductal adenocarcinoma or breast cancer (Restifo et al., 2012; Le et al., 2015; Yarchoan et al., 2017; Hilmi et al., 2018; Galon and Bruni, 2019; Duan et al., 2020).”
Chen, L. N., & Carvajal, R. D. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2124971 · Cited by 52
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 54
Luo, M., Wang, X., Wu, S., Yang, C., Su, Q., Huang, L., Fu, K., An, S., Xie, F., To, K. K. W., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01545-x · Cited by 57
“It is known that the abundance of inflammatory cells infiltrating in the tumor microenvironment (TME) is strongly associated with the efficacy of ICIs.4 There are four sub-types of TME according to the tumor mutation burden (TMB) and the expression levels of T-cell inflammatory genes.5 CRCs are usually divided into tw…”
BackgroundInfluentialQiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
“However, unlike many other immune-responsive tumors, RCC exhibits a relatively high TMB [126], making it difficult to predict RCC patients’ clinical responses to ICIs.”
BackgroundCancer vaccines as enablers of immunotherapy
Khleif, S. N., & Gupta, S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02308-2 · Cited by 65
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Cristina, V., Gómez, R. G. H., Szturz, P., Espeli, V. G., & Siano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215399 · Cited by 55
“Tumor mutational burden (TMB), a technique measuring the total number of mutations in the tumor genome by whole-exome sequencing (WES), has been shown to be a predictive marker of response to checkpoint inhibitors in different tumors [73].”
BackgroundIdentification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
“response to anti-PD-1/PD-L1 and TMB across 27 different tumor types (83).”
BackgroundBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Pietrantonio, F., Loupakis, F., Randon, G., Raimondi, A., Salati, M., Trapani, D., Pagani, F., Depetris, I., Maddalena, G., Morano, F., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0014 · Cited by 52
“The RECIST response to monotherapy with anti-PD-1/PD-L1 agents achieves one of the highest rates (up to 50%) in patients with microsatellite instability (MSI)-high advanced cancers, independently from the primary site of origin [2, 3].”
BackgroundMacpherson, A. M., Barry, S. C., Ricciardelli, C., & Oehler, M. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092967 · Cited by 56
“Interestingly, one study found a strong correlation between the objective response rate to anti–PD-1 or anti–PDL1 therapy in 27 tumor types, including ovarian cancer, and overall tumour mutational burden [303].”
Backgroundde Lima, V. A. B., Hansen, M., Spanggaard, I., Rohrberg, K. S., Hadrup, S. R., Lassen, U., & Svane, I. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.558248 · Cited by 65
“Despite encouraging results (2–4), a considerable fraction of patients undergoing ICI still do not benefit from the treatment (5) and primary or acquired ICI resistance is a significant problem that patients and clinicians face on a daily basis.”
Background1α,25(OH) 2 D 3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
Li, P., Zhu, X., Cao, G., Wu, R., Li, K., Yuan, W., Chen, B., Sun, G., Xia, X., Zhang, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003477 · Cited by 59
Zemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 55
Mao, Y., Xie, H., Lv, M., Yang, Q., Shuang, Z., Gao, F., Li, S., Zhu, L., & Wang, W. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03441-3 · Cited by 62
“[14], we selected 279 potentially relevant ORRs.”
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
Qin, Y., Huo, M., Liu, X., & Li, S. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368749 · Cited by 62
“TMB values positively correlate with the response to ICI therapy in various cancer types, including bladder cancer, non-small cell lung cancer (NSCLC), head and neck cancer and melanoma (9 – 12).”
The Identification of Immunological Biomarkers in Kidney Cancers
López-Beltrán, A., Henriques, V., Cimadamore, A., Santoni, M., Cheng, L., Gevaert, T., Blanca, A., Massari, F., Scarpelli, M., & Montironi, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00456 · Cited by 56
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
Zhang, Y., Lin, A., Li, Y., Ding, W., Meng, H., Luo, P., & Zhang, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608969 · Cited by 55
Wong, K. K., Hassan, R., & Yaacob, N. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.624742 · Cited by 57
“Cancer cells with higher mutation rates demonstrate increased odds of presenting antigens recognized by T cells as non-self (79), resulting in better response to immunotherapy (80–82).”
BackgroundAntitumor effects of iPSC-based cancer vaccine in pancreatic cancer
Ouyang, X., Liu, Y., Zhou, Y., Guo, J., Wei, T.-T., Liu, C., Lee, B., Chen, B., Zhang, A., Casey, K. M., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.04.004 · Cited by 54
“, 2018), and low mutational burden (Yarchoan et al., 2017).”
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Wei, B., Kang, J., Kibukawa, M., Arreaza, G., Maguire, M. G., Chen, L., Qiu, P., Lang, L., Aurora-Garg, D., Cristescu, R., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.01.008 · Cited by 55
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
Okada, M., Shimizu, K., & Fujii, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052594 · Cited by 52
Li, Q., Cheng, X., Zhou, C., Tang, Y., Li, F., Zhang, B., Huang, T., Wang, J., & Tu, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841977 · Cited by 53
“7% (10), indicating that there may be other factors that influence the immunity response.”
BackgroundAn Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
Liu, X., Wu, H., & Liu, Z. (2022) · Cancers · doi:10.3390/cancers14112658 · Cited by 52
“The treatment efficacy of ICIs can be predicted by tumor MSI and TMB.”
BackgroundInfluentialVaccines for immunoprevention of DNA mismatch repair deficient cancers
Hernandez‐Sanchez, A., Grossman, M., Yeung, K., Sei, S., Lipkin, S. M., & Kloor, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004416 · Cited by 53
Golkaram, M., Kuo, F., Gupta, S., Carlo, M. I., Salmans, M., Vijayaraghavan, R., Tang, C., Makarov, V., Rappold, P. M., Blum, K. A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01146-3 · Cited by 51
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Moeckel, C. M., Bakhl, K., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076710 · Cited by 54
“However, in most cancers, the response rate to ICIs is only 15–40% [72].”
BackgroundGoing to extremes: determinants of extraordinary response and survival in patients with cancer
Saner, F. A. M., Herschtal, A., Nelson, B. H., deFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51
Immunotherapy for pediatric brain tumors: past and present
Foster, J., Madsen, P. J., Hegde, M. G., Ahmed, N. M., Cole, K. A., Maris, J. M., Resnick, A. C., Storm, P. B., & Waanders, A. J. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz077 · Cited by 51
Magri, V., Gottfried, T., Segni, M. D., Urban, D., Peled, M., Daher, S., Stoff, R., Bar, J., & Onn, A. (2019) · Cancer Management and Research · doi:10.2147/cmar.s210958 · Cited by 51
Kang, B. W., & Chau, I. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000791 · Cited by 55
NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes
Becker, J. P., Helm, D., Rettel, M., Stein, F., Hernandez‐Sanchez, A., Urban, K., Gebert, J. F., Kloor, M., Neu‐Yilik, G., Doeberitz, M. V. K., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102389 · Cited by 53
Khouzam, R. A., Rao, R. S. P., Venkatesh, G. H., Zeinelabdin, N. A., Buart, S., Meylan, M., Nimmakayalu, M. A., Terry, S., & Chouaïb, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680435 · Cited by 57
“Indeed, PDAs have been shown to harbor low tumor mutational burden (TMB), especially in comparison with certain cancer types (43).”
ResultJiang, T., Chen, J., Xu, X., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., Yao, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01479-4 · Cited by 57
Oh, C. R., Kim, J. E., Hong, Y. S., Kim, S. Y., Ahn, J. B., Baek, J. Y., Lee, M. A., Kang, M. J., Cho, S., Beom, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33966 · Cited by 51
Sinha, N., Sinha, S., Valero, C., Schäffer, A. A., Aldape, K., Litchfield, K., Chan, T. A., Morris, L. G. T., & Ruppin, E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2542 · Cited by 54
Zhang, N., Zhang, H., Wang, Z., Dai, Z., Zhang, X., Cheng, Q., & Liu, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691811 · Cited by 63
“Further, TMEscores were significantly associated with CYT (Figures 6K, L).”
BackgroundInfluentialNeoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy
Richard, G., Princiotta, M. F., Bridon, D. P., Martin, W. D., Steinberg, G. D., & Groot, A. S. D. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2012456 · Cited by 53
“developed a predictive algorithm that is based on total mutational burden, and proposed that this algorithm could be used to design future CPI trials [22].”
MethodRodrigo, J. P., Sánchez‐Canteli, M., Otero‐Rosales, M., Martínez‐Camblor, P., Hermida‐Prado, F., & Garcia-Pedrero, J. M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04937-x · Cited by 55
“This is exemplified by the direct correlation between the mean TMB and the objective response rate observed across 27 tumor types [37].”
BackgroundExosomes as drug delivery systems in glioma immunotherapy
Hao, X., Wang, S., Wang, L., Li, J., Li, Y., & Liu, J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02611-4 · Cited by 50
“However, GBM exhibits a low TMB and neoantigen burden, resulting in limited therapeutic targets for the immune system [23, 24] (Fig.”
BackgroundPrecision oncology: separating the wheat from the chaff
Remón, J., & Dienstmann, R. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000446 · Cited by 52
“Similarly, recent studies have linked mutational signatures rather than single gene alterations as predictive biomarkers of response to immunotherapies.(76) At the end of the day, multidisciplinary molecular tumour boards are crucial for providing objective evidence-based translation of observed molecular alterations…”
BackgroundIdentification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer
Leko, V., McDuffie, L. A., Zheng, Z., Gartner, J. J., Prickett, T. D., Apolo, A. B., Agarwal, P. K., Rosenberg, S. A., & Lu, Y.-C. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801022 · Cited by 50
Mechanisms of immunogenicity in colorectal cancer
Sillo, T. O., Beggs, A. D., Morton, D. G., & Middleton, G. (2019) · British journal of surgery · doi:10.1002/bjs.11204 · Cited by 53
Mauriello, A., Zeuli, R., Cavalluzzo, B., Petrizzo, A., Tornesello, M. L., Buonaguro, L., Ceccarelli, M., Tagliamonte, M., & Buonaguro, L. (2019) · Cancers · doi:10.3390/cancers11121824 · Cited by 53
Checkpoint inhibitors in AML: are we there yet?
Ghosh, A., Barba, P., & Perales, M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16358 · Cited by 61
“Studies have shown that polyclonally expanded T cells might recognize tumor cells that have a higher mutation burden (i.e., the total number of mutations per coding area of the tumor genome), which have higher odds of presenting antigens that evoke recognition as non-self (Yarchoan et al., 2017).”
BackgroundNoh, B., Kwak, J. Y., & Eom, D. (2020) · BMC Cancer · doi:10.1186/s12885-020-6553-9 · Cited by 55
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma
Attalla, K., Weng, S., Voss, M. H., & Hakimi, A. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.002 · Cited by 58
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
Pérez‐Romero, K., Rodríguez, R. M. A., Amedei, A., Barceló‐Coblijn, G., & Lopez, D. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155521 · Cited by 55
“In general, response to checkpoint inhibitors is better if cancer cells express high levels of immunosuppressive molecules [65,66], in the presence of high levels of inflammatory molecules within the TME [67], or when cancer cells show a high mutational burden and high-level microsatellite instability (MSI-high), caus…”
BackgroundMuraro, E., Fanetti, G., Lupato, V., Giacomarra, V., Steffan, A., Gobitti, C., Vaccher, E., & Franchin, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103424 · Cited by 56
Tan, Z.-L., Yue, C., Ji, S., Zhao, C., Jia, R., Zhang, Y., Liu, R., Li, D., Yu, Q., Li, P., et al. (2021) · The Oncologist · doi:10.1002/onco.13981 · Cited by 51
Gp-100 as a Novel Therapeutic Target in Uveal Melanoma
Martínez-Pérez, D., Viñal, D., Solares, I., Espinosa, E., & Feliú, J. (2021) · Cancers · doi:10.3390/cancers13235968 · Cited by 49
“Another significant difference between UM and CM is the very low tumor mutational burden of the former, which may, to some extent, explain the lower efficacy of immunotherapy in UMs [3].”
BackgroundMartori, C., Sánchez-Moral, L., Paul, T., Pardo, J. C., Pous, A. F., de Porras, V. R., & Sarrias, M. (2022) · Cancers · doi:10.3390/cancers14020440 · Cited by 53
“Nevertheless, as previously stated, several clinical trials have evaluated the efficacy of ICIs in mPC patients who were not selected based on predictive molecular biomarkers, either as single agents or in combination with other checkpoint inhibitors or with other therapies with limited overall activity and inconclusi…”
BackgroundInfluentialTumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma
Zhou, Z., Chen, M.-J. M., Luo, Y., Mojumdar, K., Peng, X., Chen, H., Kumar, S. V., Akbani, R., Lu, Y., & Liang, H. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.012 · Cited by 53
“However, the response rate varies by cancer type, ranging from 10% to 60% (Ansell et al., 2015; Yarchoan et al., 2017), and the average objective response rate is only 26% across all cancer types (Shen et al.”
BackgroundGarassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., Hui, R., Garon, E. B., Horinouchi, H., Sugawara, S., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100431 · Cited by 46
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
Zhang, W., Wang, P., & Pang, Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4625 · Cited by 64
“The results revealed improved mOS and a 31% reduction in the risk of progression or death after camrelizumab-treatment compared with after chemotherapy, as well as superior ORR (20.2% vs. 6.4”
BackgroundInfluentialMola, S., Pandolfo, C., Sica, A., & Porta, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186866 · Cited by 47
An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma
Huang, X., Chi, H., Gou, S., Guo, X., Li, L., Peng, G., Zhang, J., Xu, J., Nian, S., & Yuan, Q. (2023) · Genes · doi:10.3390/genes14010124 · Cited by 54
“The total number of non-synonymous mutations in somatic cells, including frameshift mutations, insertions, point mutations, and deletions, is commonly characterized as TMB [65,66].”
BackgroundTargeting the tumor microenvironment, a new therapeutic approach for prostate cancer
Fang, B., Lu, Y., Li, X., Yu, W., Ye, D., Wei, G., & Zhu, Y. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00825-z · Cited by 61
“Lacking of immune effector cells in fi ltration, few tumor-speci fi c antigens and the suppressive TME may account for this [13, 14].”
Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 54
Rose, A. A. N., Armstrong, S. M., Hogg, D., Butler, M. O., Saibil, S. D., Arteaga, D. P., Muniz, T. P., Kelly, D., Ghazarian, D., King, I. F. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001642 · Cited by 51
Qi, Q., Song, Q., Cheng, Y., & Wang, N. (2021) · Cancer Management and Research · doi:10.2147/cmar.s333190 · Cited by 51
“With the application of immune therapy targeting programmed death 1 (PD1) and programmed death-ligand 1(PD-L1), tumor immunotherapy is extensively clarified as an important part of combined therapy of tumor in recent years.(11) The correlation between systemic inflammation and the local immune response was recognized…”
The immunology of low-grade gliomas
Haddad, A. F., Young, J. S., Oh, J. Y., Okada, H., & Aghi, M. K. (2022) · Neurosurgical FOCUS · doi:10.3171/2021.11.focus21587 · Cited by 49
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi, B., El Ghanmi, A., Kandoussi, S., Ghouzlani, A., & Badou, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978195 · Cited by 46
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 50
Current Status of Immunotherapies for Treating Pancreatic Cancer
Wu, A. A., Jaffee, E. M., & Lee, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0811-5 · Cited by 50
Self-citationPossible Biomarkers for Cancer Immunotherapy
Otoshi, T., Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2019) · Cancers · doi:10.3390/cancers11070935 · Cited by 48
“In fact, it is one of the emerging biomarkers for predicting the response to immunotherapy [19].”
BackgroundRole of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 48
“The potential correlation of number of nonsynonymous mutations and sensitivity to immunotherapy prompted the evaluation of the efficacy of ICI in patients with high-frequency microsatellite instability (MSI-H) [15],”
BackgroundInterventional Radiology for Local Immunotherapy in Oncology
Tselikas, L., Champiat, S., Sheth, R. A., Yevich, S., Ammari, S., Deschamps, F., Farhane, S., Roux, C., Susini, S., Mouraud, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4073 · Cited by 48
“While systemic immunotherapies have revolutionized cancer care, objective response rates for many cancer histologies remain low (5), in part due to barriers imposed upon the immune system by immunosuppressive elements within the tumor microenvironment.”
BackgroundThe role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
Naqash, A. R., Kihn-Alarcón, A. J., Stavraka, C., Kerrigan, K. C., Vareki, S. M., Pinato, D. J., & Puri, S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6427 · Cited by 54
“At present, two predictive biomarkers, PD-L1 immunohistochemistry (IHC) and tumor mutation burden (TMB) are utilized in clinical practice, although TMB has demonstrated mixed results as an effective predictive biomarker (1,2).”
MethodTruong, N. T., Gargett, T., Brown, M. P., & Ebert, L. M. (2021) · Cancers · doi:10.3390/cancers13092225 · Cited by 49
“For example, pancreatic carcinoma and sarcoma have very low somatic mutation rates and are largely non-responsive to antiPD1 immunotherapy, which relies on a pre-existing anti-tumour immune response for efficacy [20].”
BackgroundCD8 + T cell immunity blocks the metastasis of carcinogen-exposed breast cancer
Li, K., Li, T., Feng, Z., Huang, M., Wei, L., Yan, Z., Long, M. D., Hu, Q., Wang, J., Liu, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd8936 · Cited by 53
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Vukadin, S., Khaznadar, F., Kizivat, T., Včev, A., & Smolić, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070835 · Cited by 49
“, it was reported that TMB across 27 different tumor types significantly correlated with a positive response to PD-1-directed immunotherapy in patients in whom PD-L1 expression was not analyzed [52].”
BackgroundCunningham‐Bussel, A., Wang, J., Prisco, L. C., Martin, L. W., Vanni, K. M. M., Zaccardelli, A., Nasrallah, M., Gedmintas, L., MacFarlane, L. A., Shadick, N. A., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.41949 · Cited by 54
“Patients with rapidly fatal malignancies may not have had the chance to develop a rheumatic irAE, which can develop a median of 5 months after the initiation of ICI therapy (38).”
BackgroundStrippoli, S., Fanizzi, A., Quaresmini, D., Nardone, A., Armenio, A., Figliuolo, F., Filotico, R., Fucci, L., Mele, F., Traversa, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.686308 · Cited by 51
Friedman, C. F., Spencer, C. N., Cabanski, C. R., Panageas, K. S., Wells, D. K., Ribas, A., Tawbi, H. A., Tsai, K. K., Postow, M. A., Shoushtari, A. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003853 · Cited by 50
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
Pirš, B., Škof, E., Smrkolj, V., & Smrkolj, Š. (2022) · Cancers · doi:10.3390/cancers14030631 · Cited by 52
Haddad, A. F., Young, J. S., Gill, S. A., & Aghi, M. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.019 · Cited by 50
Wolf, N. K., Blaj, C., Picton, L. K., Snyder, G., Zhang, L., Nicolai, C. J., Ndubaku, C. O., McWhirter, S. M., García, K. C., & Raulet, D. H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200568119 · Cited by 48
“However, some tumors lack many neoantigens for T cell recognition (4, 5), or acquire defects in antigen presentation or major histocompatibility complex class I (MHC I) expression before or during therapy that confer resistance (6–10).”
BackgroundDiagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma
Weaver, C., Satter, K. B., Richardson, K. P., Tran, L. K. H., Tran, P. M. H., & Purohit, S. B. (2022) · Biomedicines · doi:10.3390/biomedicines10112953 · Cited by 55
Cheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 50
“UM expresses lower TMB and antigenicity than cutaneous melanoma, leading to a poor response to ICI therapy [204, 205].”
BackgroundMiyazaki, T., Ishikawa, E., Matsuda, M., Sugii, N., Kohzuki, H., Akutsu, H., Sakamoto, N., Takano, S., & Matsumura, A. (2020) · Brain Tumor Pathology · doi:10.1007/s10014-020-00357-z · Cited by 50
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.